Abstract

Programmable nucleases have enabled rapid and accessible genome engineering in eukaryotic cells and living organisms. However, their delivery into human blood cells can be challenging. Here, we have utilized “nanoblades,” a new technology that delivers a genomic cleaving agent into cells. These are modified murine leukemia virus (MLV) or HIV-derived virus-like particle (VLP), in which the viral structural protein Gag has been fused to Cas9. These VLPs are thus loaded with Cas9 protein complexed with the guide RNAs. Highly efficient gene editing was obtained in cell lines, IPS and primary mouse and human cells. Here, we showed that nanoblades were remarkably efficient for entry into human T, B, and hematopoietic stem and progenitor cells (HSPCs) thanks to their surface co-pseudotyping with baboon retroviral and VSV-G envelope glycoproteins. A brief incubation of human T and B cells with nanoblades incorporating two gRNAs resulted in 40 and 15% edited deletion in the Wiskott-Aldrich syndrome (WAS) gene locus, respectively. CD34+ cells (HSPCs) treated with the same nanoblades allowed 30–40% exon 1 drop-out in the WAS gene locus. Importantly, no toxicity was detected upon nanoblade-mediated gene editing of these blood cells. Finally, we also treated HSPCs with nanoblades in combination with a donor-encoding rAAV6 vector resulting in up to 40% of stable expression cassette knock-in into the WAS gene locus. Summarizing, this new technology is simple to implement, shows high flexibility for different targets including primary immune cells of human and murine origin, is relatively inexpensive and therefore gives important prospects for basic and clinical translation in the area of gene therapy.

Highlights

  • Gene-editing approaches aim at directly manipulating the genome allowing gene disruption, gene correction, or transgene integration at a precise endogenous genomic locus

  • We developed the nanotechnology called nanoblades, which are virus-like particles (VLPs) derived from the murine leukemia virus (MLV) (Mangeot et al, 2019)

  • We have demonstrated that nanoblades derived from HIV and MLV VLPs can deliver the Cas9-guide RNA(s) (gRNA) ribonucleoproteins into human T, B cells and hematopoietic stem and progenitor cells (HSPCs) in

Read more

Summary

Introduction

Gene-editing approaches aim at directly manipulating the genome allowing gene disruption, gene correction, or transgene integration at a precise endogenous genomic locus. The DSB induced by endonucleases at a specific locus can be sealed by HDR when an exogenous DNA template is provided carrying homology arms to the site of the DSB. This template is provided either by integration-deficient lentiviral vectors (IDLVs), recombinant adeno-associated viruses serotype 6 (rAAV6) or by electroporation of single-stranded DNA, or oligonucleotides (ODN) (Hendel et al, 2015a; Wang et al, 2015; Antony et al, 2018). Since HDR is restricted to the S/G2 phase of the cell cycle, gene modification in primary cells remains a challenge for the scientific community

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call